The National Cancer Society Malaysia has made an urgent call for the government to establish a comprehensive national co-screening programme to tackle the growing epidemic of cardio-renal-metabolic diseases affecting Malaysians. The health advocacy group argues that a coordinated approach is essential to detect, prevent, and manage these interlinked conditions—which encompass heart disease, kidney dysfunction, and metabolic disorders such as diabetes—before they overwhelm the healthcare system and drain family finances.
The urgency of this appeal stems from alarming epidemiological trends that paint a sobering picture of public health. Recent screening data from a project conducted in the Klang Valley revealed that nearly nine in ten Malaysians surveyed carried at least two concurrent cardio-renal-metabolic risk factors, indicating that these diseases do not operate in isolation but rather form a dangerous cluster of reinforcing conditions. The findings underscore a fundamental shift in how Malaysia's chronic disease burden operates: rather than individuals presenting with single, manageable ailments, the population is increasingly burdened by multiple overlapping health challenges that accelerate one another's progression.
The Saring@Komuniti project, a collaboration between the National Cancer Society Malaysia and Boehringer Ingelheim conducted with Ministry of Health support, screened 5,000 residents from economically disadvantaged communities in the Klang Valley last year. The results were striking and warrant serious policy attention. The study found that 41.3 per cent of participants were classified as obese, while an additional 28.8 per cent were overweight, meaning roughly seven in ten carried excessive body weight. Perhaps more concerning were the metabolic findings: 34.5 per cent had progressed to pre-diabetes, whilst 35.1 per cent had already developed diabetes, suggesting that Malaysia harbours a vast hidden reservoir of blood sugar dysfunction that remains undiagnosed and therefore untreated in the broader population.
These numbers acquire greater significance when viewed against the backdrop of Malaysia's historical chronic disease trajectory. Chronic kidney disease prevalence has surged from 9.1 per cent in 2011 to 15.5 per cent in 2019—a rise of more than 70 per cent in less than a decade. Equally alarming, the number of Malaysians dependent on dialysis treatment has more than tripled over the past twenty years, reflecting not only increasing disease incidence but also inadequate prevention and early detection mechanisms. For a middle-income country bearing the cost of providing dialysis to growing populations, these trends represent both a public health catastrophe and an unsustainable fiscal burden.
The interconnected nature of these diseases creates a vicious cycle that current healthcare structures are poorly positioned to address. Cardiovascular disease, chronic kidney disease, and diabetes share fundamental underlying risk factors—obesity, hypertension, dyslipidaemia, and inflammation—which means that individuals with one condition are at dramatically elevated risk for the others. Furthermore, each disease potentiates the others; uncontrolled diabetes damages blood vessels and kidneys, damaged kidneys elevate blood pressure and cardiovascular risk, and cardiovascular disease reduces kidney perfusion and function. Current healthcare delivery systems, organised around disease-specific silos, frequently miss these connections entirely, allowing patients to develop multiple advanced conditions simultaneously whilst receiving fragmented, uncoordinated care.
The policy recommendations emerging from the National Cancer Society Malaysia's analysis identify two critical structural deficiencies requiring urgent remediation. First, Malaysia lacks systematic integrated co-screening programmes that simultaneously assess risk across cardiovascular, renal, and metabolic domains. Instead, individuals may undergo separate screening for diabetes in one clinic, blood pressure assessment at another location, and kidney function testing at a third—assuming they access screening at all. This patchwork approach ensures that opportunities for identifying clusters of risk are routinely missed. Second, even when abnormal screening results are identified, patients frequently encounter fragmented referral pathways, inconsistent follow-up mechanisms, and structural barriers to continuity of care that prevent them from progressing from screening to diagnosis to treatment to sustained management.
Addressing these systemic failures requires deliberate policy action and resource allocation. The National Cancer Society Malaysia has proposed that integrated CRM co-screening programmes be scaled nationwide, embedded into routine health checks conducted at both public clinics and workplace settings. This would entail standardising risk assessment protocols, training frontline health workers in identifying clusters of interconnected risk factors, and establishing clear pathways ensuring patients with abnormal results receive appropriate referral and follow-up. The feasibility of this approach is evident from the successful Klang Valley pilot, which demonstrated that economically disadvantaged communities respond positively to accessible screening when culturally sensitive methodologies are employed.
The financial implications of current trajectories warrant government attention. Chronic kidney disease management consumes substantial healthcare resources, with dialysis constituting a particularly expensive intervention when chronic disease could have been prevented or delayed through earlier detection and intervention. Similarly, the cardiovascular and diabetic complications cascading from undetected metabolic dysfunction generate substantial costs in hospitalisations, medications, and lost productivity. Investment in upstream integrated screening and coordinated care—whilst requiring initial outlays—would generate long-term savings through disease prevention and complications avoidance, thereby freeing resources for other health priorities.
Dr Murallitharan Munisamy, Managing Director of the National Cancer Society Malaysia, articulated the strategic imperative clearly: Malaysia possesses an opportunity to transition from a healthcare model that manages individual diseases in isolation to one that recognises cardiovascular, kidney, and metabolic health as a unified continuum requiring coordinated intervention. This paradigm shift represents not merely incremental improvement but rather a fundamental restructuring of how the healthcare system conceptualises and addresses chronic disease. Early detection must be accompanied by robust follow-up mechanisms and sustained long-term care pathways; without these supporting structures, screening alone becomes an exercise in identifying disease whilst providing no mechanism for remedy.
The private sector perspective adds weight to these arguments. Boehringer Ingelheim, a major biopharmaceutical company operating across human and animal health divisions, emphasises that cardiovascular, kidney, and metabolic conditions share such profound interconnections that attempting to treat them separately violates fundamental pathophysiological principles. Industry recognition of these relationships suggests that therapeutic innovation and treatment paradigms are increasingly shifting toward integrated management approaches, further validating the National Cancer Society Malaysia's policy recommendations.
For Malaysian policymakers, the evidence accumulating from both local research and international experience points toward a clear imperative: the current fragmented approach to chronic disease prevention and management is inadequate for the challenges posed by rising cardio-renal-metabolic disease burden. The Klang Valley screening data provides not merely evidence of disease prevalence but a blueprint for intervention. The National Cancer Society Malaysia's policy briefs translate this evidence into actionable recommendations that, if implemented systematically, could bend the trajectory of chronic disease burden, reduce preventable complications, ease pressure on healthcare infrastructure, and ultimately improve the health and longevity of Malaysian populations. The investment required pales in comparison to the costs of inaction.
